GLP-1 Market
LLY $1181.89 ▲ +2.7% NVO $38.62 ▲ +1.2% PFE $28.41 ▲ +0.8% VKTX $36.75 ▼ -11.8% KLRA $11.98 ▼ -8.8% GPCR $36.02 ▲ +0.2% RHHBY $54.80 ▼ -0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AEB1102

AEB1102

Company
Immedica Pharma AB
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 25, 2026

Trial details
  • Completed NCT NCT02488044

    A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

    Not yet reported, Not yet reported Aeglea Biotherapeutics 16 participants Est. completion 2019-02 9 sites Stand-alone
    Other conditions: Arginase I Deficiency, Hyperargininemia
    View official trial listing →
  • Completed NCT NCT02561234

    A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

    Not yet reported Immedica Pharma AB 76 participants Est. completion 2019-05-28 11 sites Stand-alone
    Other conditions: Advanced Cancers
    View official trial listing →
  • Completed NCT NCT02732184

    A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

    Not yet reported Immedica Pharma AB 21 participants Est. completion 2017-11-01 10 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT03371979

    Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

    Not yet reported, Not yet reported Aeglea Biotherapeutics 68 participants Est. completion 2021-01-01 22 sites Stand-alone
    Other conditions: Small-cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03378531

    A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency

    Not yet reported Immedica Pharma AB 14 participants Est. completion 2022-12-15 7 sites Stand-alone
    Other conditions: Arginase I Deficiency, Hyperargininemia
    View official trial listing →
  • Completed NCT NCT03921541

    Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

    Not yet reported Immedica Pharma AB 32 participants Est. completion 2023-02-01 32 sites Stand-alone
    Other conditions: Arginase I Deficiency, Hyperargininemia
    View official trial listing →
  • Terminated NCT NCT05676853

    A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

    Not yet reported Aeglea Biotherapeutics 3 participants Est. completion 2023-04-27 1 site Stand-alone
    Other conditions: Arginase I Deficiency, Hyperargininemia
    View official trial listing →
  • Completed NCT NCT06582524

    Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency

    Not yet reported Immedica Pharma AB 3 participants Est. completion 2025-06-17 3 sites Stand-alone
    Other conditions: Arginase 1 Deficiency
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: AEB1102, Co-ArgI-PEG, Pegzilarginase

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.